-
1.
公开(公告)号:EP2970443A2
公开(公告)日:2016-01-20
申请号:EP14770483.7
申请日:2014-03-14
申请人: Gill, Parkash, S. , Liu, Ren
发明人: Gill, Parkash, S. , Liu, Ren
IPC分类号: C07K16/00 , C12P21/08 , A61K39/395 , A61K39/00
CPC分类号: C07K16/28 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K47/6898 , A61K49/0032 , A61K49/0058 , A61K2039/505 , C07K16/18 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/57492 , G01N2333/705
摘要: This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting cell surface GRP78 expressed on tumor cells, tumor endothelial cells, and tumor initiating cancer cells. These anti-GRP78 antibodies, or antigen-binding fragments thereof, have a high affinity for GRP78 and are less immunogenic compared to their unmodified parent antibodies in a given species, e.g., a human, and function to inhibit GRP78. Importantly, these isolated novel antibodies and antigen-binding fragments thereof, attenuate PI3K signaling and promote apoptosis in tumor cells, while leaving normal cells unaffected. The antibodies and antigen-binding fragments are useful for UPR-targeted cancer therapeutic treatments.